Table 2.

Maintenance phase lacosamide dosing for overall study population and age group subanalysis (mFAS)

Dose	Subjects n (%)
Overall mFAS (n = 416): mean (SD) dosage 279.2 (101.3) mg/day; median dose 300 mg/day (range 50–400 mg/day)
<200 mg/day	44 (10.6)
200–300 mg/day	229 (55.0)
>300–400 mg/day	143 (34.4)
Age <65 years (n = 337): mean (SD) dosage 283.7 (99.7) mg/day; median (range) dose 300 (50–400) mg/day
<200 mg/day	29 (8.6)
200–300 mg/day	187 (55.5)
>300–400 mg/day	121 (35.9)
Age ≥65 years (n = 79): mean (SD) dosage 260.1 (106.6) mg/day; median dose 250 (range 50–400) mg/day.
<200 mg/day	15 (19.0)
200–300 mg/day	42 (53.2)
>300–400 mg/day	22 (27.8)

mFAS, modified full analysis set; SD, standard deviation.